PPARα/γ agonists like saroglitazar improve insulin resistance, suppress SREBP1c-mediated lipogenesis, and attenuate oxidative stress via nuclear factor erythroid 2 like 2 (NRF2) activation, demonstrating efficacy in preclinical steatosis and fibrosis models [63]. This evidence concerns the gene SREBF1 and steatosis.